
Immune therapy reduces risk of recurrence in aggressive breast cancer
An immune therapy for the most aggressive form of breast cancer can substantially reduce the risk of the disease returning, according to a clinical trial led by Professor Peter Schmid of St Bartholomew’s Hospital and Queen Mary University of London.